12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Crofelemer regulatory update

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP, Morrisville, N.C.) said FDA extended the PDUFA date by 3 months for an NDA for crofelemer to treat diarrhea in HIV/AIDS patients on antiretroviral therapy. The new date is Sept. 5; it was June 5. The application has Priority Review. According to Salix, FDA...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >